​
​

Lexeo Therapeutics (LXEO) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

LXEO Stock Forecast

Lexeo Therapeutics stock forecast is as follows: an average price target of $28.00 (represents a 365.12% upside from LXEO’s last price of $6.02) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

LXEO Price Target

The average price target for Lexeo Therapeutics (LXEO) is $28.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $28.00 to $28.00. This represents a potential 365.12% upside from LXEO's last price of $6.02.

LXEO Analyst Ratings

Buy

According to 2 Wall Street analysts, Lexeo Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for LXEO stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Lexeo Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 12, 2024Brian SkorneyRobert W. Baird$28.00$18.1953.93%365.12%
Row per page
Go to

The latest Lexeo Therapeutics stock forecast, released on Jun 12, 2024 by Brian Skorney from Robert W. Baird, set a price target of $28.00, which represents a 53.93% increase from the stock price at the time of the forecast ($18.19), and a 365.12% increase from LXEO last price ($6.02).

Lexeo Therapeutics Price Target by Period

1M3M12M
# Anlaysts--1
Avg Price Target--$28.00
Last Closing Price$6.02$6.02$6.02
Upside/Downside-100.00%-100.00%365.12%

In the current month, the average price target of Lexeo Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Lexeo Therapeutics's last price of $6.02. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Jun 06, 2024H.C. Wainwright-BuyInitialise
Mar 12, 2024RBC CapitalOutperformOutperformHold
Row per page
Go to

Lexeo Therapeutics's last stock rating was published by H.C. Wainwright on Jun 06, 2024. The company Initialise its LXEO rating from "null" to "Buy".

Lexeo Therapeutics Financial Forecast

Lexeo Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
# Analysts-----------
Surprise %-----------

Lexeo Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. LXEO's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Lexeo Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EBITDA-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

undefined analysts predict LXEO's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Lexeo Therapeutics's previous annual EBITDA (undefined) of $NaN.

Lexeo Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
Net Income-----------
Avg Forecast$-25.46M$-26.45M$-25.46M$-24.47M$-25.46M$-24.71M$-25.05M$-24.55M$-25.32M$-22.43M$-22.82M
High Forecast$-25.46M$-26.45M$-25.46M$-24.47M$-25.46M$-24.71M$-25.05M$-17.49M$-16.56M$-19.13M$-22.82M
Low Forecast$-25.46M$-26.45M$-25.46M$-24.47M$-25.46M$-24.71M$-25.05M$-31.28M$-32.14M$-25.40M$-22.82M
Surprise %-----------

Lexeo Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. LXEO's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Lexeo Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
SG&A-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

Lexeo Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to LXEO last annual SG&A of $NaN (undefined).

Lexeo Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EPS-----------
Avg Forecast$-0.77$-0.80$-0.77$-0.74$-0.77$-0.75$-0.76$-0.74$-0.77$-0.68$-0.69
High Forecast$-0.77$-0.80$-0.77$-0.74$-0.77$-0.75$-0.76$-0.53$-0.50$-0.58$-0.69
Low Forecast$-0.77$-0.80$-0.77$-0.74$-0.77$-0.75$-0.76$-0.95$-0.97$-0.77$-0.69
Surprise %-----------

According to undefined Wall Street analysts, Lexeo Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to LXEO previous annual EPS of $NaN (undefined).

LXEO Forecast FAQ

Is Lexeo Therapeutics a good buy?

Yes, according to 2 Wall Street analysts, Lexeo Therapeutics (LXEO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of LXEO's total ratings.

What is LXEO's price target?

Lexeo Therapeutics (LXEO) average price target is $28 with a range of $28 to $28, implying a 365.12% from its last price of $6.02. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Lexeo Therapeutics stock go up soon?

According to Wall Street analysts' prediction for LXEO stock, the company can go up by 365.12% (from the last price of $6.02 to the average price target of $28), up by 365.12% based on the highest stock price target, and up by 365.12% based on the lowest stock price target.

Can Lexeo Therapeutics stock reach $9?

LXEO's average twelve months analyst stock price target of $28 supports the claim that Lexeo Therapeutics can reach $9 in the near future.

What are Lexeo Therapeutics's analysts' financial forecasts?

Lexeo Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-99.768M (high $-92.706M, low $-106M), average SG&A $0 (high $0, low $0), and average EPS is $-3.018 (high $-2.804, low $-3.221). LXEO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-102M (high $-102M, low $-102M), average SG&A $0 (high $0, low $0), and average EPS is $-3.08 (high $-3.08, low $-3.08).